Can a drug keep sarcoma from returning? new trial hopes so

NCT ID NCT06892678

Recruiting now Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether DFMO, a drug taken by mouth, can help prevent cancer from coming back in people with relapsed Ewing sarcoma or osteosarcoma who have finished all planned treatment and show no signs of disease. The trial will enroll 15 participants under age 40. The main goal is to see if giving DFMO as maintenance therapy is feasible and safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DFMO (difluoromethylornithine)
What this could lead to: If successful, this could provide a maintenance option to help keep relapsed sarcoma from coming back after standard treatment.
What could go wrong: This is a very small early-phase trial with only 15 participants, so results may not apply widely. DFMO may not prevent recurrence and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING'S TUMOR RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING'S TUMOR RECURRENT OSTEOSARCOMA RECURRENT

Contacts and locations

Locations

Montefiore Medical Center
RECRUITING

The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.